Baxalta opens UK headquarters in Staines, Middlesex

Published: 22-Jul-2015
Research & Development Finance Pharmaceutical

Plans to employ around 100 people


Baxalta, a new biopharmaceutical company formed following its separation from Baxter International, of Deerfield, Illinois, US, has opened a UK headquarters in Staines, Middlesex, with plans to employ around 100 people.

Launched on 1 July, the US$6bn global biopharmaceutical company is focused on the development of therapies for orphan diseases and under-served conditions in haematology, immunology and oncology.

Baxalta, which has a strong foothold in haematology and immunology, aims to expand its oncology portfolio for patients with limited treatment options. The company plans to launch 20 new products across the globe by 2020.

The Baxalta Global Innovation and R&D Centre is located in Cambridge, Massachusetts.

Headquartered in Northern Illinois, Baxalta employs 16,000 people worldwide.

  • Companies:
  • Baxalta
See more

You may also like

Finance

Shareholders approve Shire's merger with Baxalta

Read more
Will create 'the leading global biotechnology company in rare diseases and other highly specialised conditions', the firms say

Trending Articles

  1. Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
  2. Aurobindo Pharma signs $25m respiratory drug development and commercialisation deal with global pharma company The companies will co-develop and commercialise respiratory therapeutics, diversifying Aurobindo's current portfolio
  3. Vetter strengthens senior management team for growth Three new managing directors to support global sustainable development

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

You may also like

Finance

Shareholders approve Shire's merger with Baxalta

Will create 'the leading global biotechnology company in rare diseases and other highly specialised conditions', the firms say
Finance

Shire to buy Baxalta for US$32bn

Creating a global leader in rare diseases
Research & Development

Baxalta agrees $1.6bn cancer deal with Symphogen

Will advance novel therapeutics against six targets
Research & Development

Baxalta opens Global Innovation Centre in Cambridge, MA, US

Will serve as the firm's HQ for R&D, oncology, biosimilars and business development
Finance

Shire makes hostile all-stock US$30bn bid for Baxalta

To create the leading global biotechnology company focused on rare diseases
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
Subscribe now